<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00370500</url>
  </required_header>
  <id_info>
    <org_study_id>D1449L00029</org_study_id>
    <secondary_id>EudraCT-Nr: 2005-006151-20</secondary_id>
    <nct_id>NCT00370500</nct_id>
  </id_info>
  <brief_title>Quetiapine and the Dopaminergic Epigenetic Control</brief_title>
  <official_title>Quetiapine and the Dopaminergic Epigenetic Control - a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-N端rnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Erlangen-N端rnberg Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND:&#xD;
&#xD;
      Epigenetic modifications such as DNA-methylation and histone acetylation are known to be&#xD;
      involved in the pathophysiology of schizophrenia. Aim of the present study is to investigate&#xD;
&#xD;
        1. whether differences in the methylation pattern of the promoters of dopaminergic genes&#xD;
           exist between schizophrenic patients and healthy controls and&#xD;
&#xD;
        2. whether treatment with the second generation antipsychotic quetiapine leads to changes&#xD;
           in the methylation pattern of those genes in patients suffering from schizophrenia.&#xD;
&#xD;
      STUDY DESIGN AND METHODS:&#xD;
&#xD;
      50 male patients and 50 male controls are to be enrolled into the study. Patients will be&#xD;
      treated with quetiapine for 3 weeks. Blood samples will be drawn before treatment and after&#xD;
      three weeks to measure DNA-methylation status. Clinical characterisation includes PANSS,&#xD;
      AIMS, BDI. Healthy probands will not be treated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary variable is the amount of methylated vs. unmethylated promoter specific DNA in the DAT gene of patients before and after treatment with quetiapine (within group comparison).</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>There is only one arm in this study. All probands receive quetiapine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine fumarate</intervention_name>
    <description>Dosage and frequency are judged by the study physician. The dosage must not excess 800mg/d.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Seroquel(R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        For inclusion in the study subjects must fulfil all of the following criteria:&#xD;
&#xD;
          1. Provision of written informed consent&#xD;
&#xD;
          2. A diagnosis of schizophrenia by Diagnostic and Statistical Manual of Mental Disorders-&#xD;
             Fourth Edition (DSM-IV)&#xD;
&#xD;
          3. Able to understand and comply with the requirements of the study&#xD;
&#xD;
          4. Age 18 - 65 years&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Any of the following is regarded as a criterion for exclusion from the study:&#xD;
&#xD;
          1. Any DSM-IV Axis I disorder not defined in the inclusion criteria&#xD;
&#xD;
          2. Patients who, in the opinion of the investigator, pose an imminent risk of suicide or&#xD;
             a danger to self or others&#xD;
&#xD;
          3. Known intolerance or lack of response to quetiapine fumarate, as judged by the&#xD;
             investigator&#xD;
&#xD;
          4. Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding&#xD;
             enrolment including but not limited to: ketoconazole, itraconazole, fluconazole,&#xD;
             erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir,&#xD;
             fluvoxamine and saquinavir&#xD;
&#xD;
          5. Use of any of the following cytochrome P450 inducers in the 14 days preceding&#xD;
             enrollment including but not limited to: phenytoin, carbamazepine, barbiturates,&#xD;
             rifampin, St. John's Wort, and glucocorticoids&#xD;
&#xD;
          6. Administration of a depot antipsychotic injection within one dosing interval (for the&#xD;
             depot) before inclusion&#xD;
&#xD;
          7. Substance or alcohol dependence at enrolment (except dependence in full remission, and&#xD;
             except for caffeine or nicotine dependence), as defined by DSM-IV criteria&#xD;
&#xD;
          8. Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV&#xD;
             criteria within 4 weeks prior to enrolment&#xD;
&#xD;
          9. Medical conditions that would affect absorption, distribution, metabolism, or&#xD;
             excretion of study treatment&#xD;
&#xD;
         10. Unstable or inadequately treated medical illness (e.g. diabetes, angina pectoris,&#xD;
             hypertension) as judged by the investigator&#xD;
&#xD;
         11. Involvement in the planning and conduct of the study&#xD;
&#xD;
         12. Previous enrolment in the present study.&#xD;
&#xD;
         13. Participation in another drug trial within 4 weeks prior enrolment into this study or&#xD;
             longer in accordance with local requirements&#xD;
&#xD;
         14. Actual treatment with clozapine or clozapine treatment during the previous three&#xD;
             month. Other antipsychotic drugs will be allowed, if intake can be terminated during&#xD;
             the two day wash out period.&#xD;
&#xD;
         15. Previous history of major head injuries or neurological disorders&#xD;
&#xD;
         16. Intake of homocysteine lowering vitamins (folate, B12, B6)&#xD;
&#xD;
         17. Renal failure&#xD;
&#xD;
         18. Intake of nutritional derivatives which influence epigenetic patterns (butyrate from&#xD;
             milk products, tea polyphenol or epigallo-catechin-3-gallate which inhibits DNMT)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Bleich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Erlangen-N端rnberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy, University Erlangen-Nuremberg</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 30, 2006</study_first_submitted>
  <study_first_submitted_qc>August 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2006</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <name_title>Stefan Bleich</name_title>
    <organization>University of Erlangen-N端rnberg</organization>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Dopamine transporter gene</keyword>
  <keyword>DNA methylation</keyword>
  <keyword>Epigenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

